×
About 344,798 results

Long COVID Costs Trillions; 'Sunburnt Challenge' Banned; Diagnosis by Fart?
https://www.medpagetoday.com/infectiousdisease/covid19/101990

Dec 1st, 2022 - Note that some links may require subscriptions. One estimate has long COVID costing the U.S. economy $3.7 trillion. (CNBC) The FDA is considering a new strategy for blood donation that may include screening gay and bisexual men for individual risks. (CNN) Responding to criticism, ProPublica says it stands by its controversial investigation (published with Vanity Fair) that pins COVID-19's origi...

Year in Review: Diffuse Large B-Cell Lymphoma
https://www.medpagetoday.com/hematologyoncology/lymphoma/101996

Dec 1st, 2022 - Second-line treatment for diffuse large B-cell lymphoma (DLBCL) got a big boost in 2022 with new indications for a pair of chimeric antigen receptor (CAR) T-cell therapies, while an antibody-drug conjugate moved one step closer to shaking up treatment in the first-line setting. CAR-T Products Move to Second-Line In April, axicabtagene ciloleucel (axi-cel; Yescarta) became the first CAR T-cell t...

Tamoxifen Ups Risk of Uterine Disease, Endometrial Cancer
https://www.medscape.com/viewarticle/984846

Dec 1st, 2022 - Tamoxifen treatment for premenopausal women with breast cancer is independently associated with an increased risk of endometrial cancer and other uterine diseases, according to findings from a large retrospective study of Korean women. After adjusting for multiple confounding variables, tamoxifen users had an almost fourfold increased risk of endometrial cancer compared with nonusers. Overall, ...

Fewer Neonatal Risks With Buprenorphine for Opioid Use Disorder in Pregnancy
https://www.medpagetoday.com/obgyn/pregnancy/101994

Dec 1st, 2022 - Buprenorphine treatment for pregnant patients with opioid use disorder (OUD) was linked with fewer neonatal risks compared with methadone therapy, but had similar maternal outcomes, an analysis of Medicaid data found. Neonatal abstinence syndrome (NAS) occurred in 52% of infants whose mothers took buprenorphine in the 30 days before delivery compared with 69% of those whose mothers took methado...

Research - Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/732835

Aerosolized glucocorticoid treatment was independently associated with bacterial isolation in these patients.

Monks and Meth; China Says Jogger Caused COVID Outbreak; Flu Deaths Close to 3,000
https://www.medpagetoday.com/infectiousdisease/covid19/101971

Nov 30th, 2022 - Note that some links may require subscriptions. All four monks at a Buddhist temple in central Thailand were defrocked after testing positive for methamphetamine use. (CBS News) New York City will begin involuntarily hospitalizing its homeless mentally ill residents, Mayor Eric Adams (D) said. (New York Times) A Minnesota woman lost part of her peripheral vision and inadvertently put her family...

The 'Too Many Toes Sign' and the Thompson Squeeze
https://www.medscape.com/viewarticle/984256

Nov 30th, 2022 - This transcript has been edited for clarity. Matthew F. Watto, MD: Welcome back to The Curbsiders. I'm Dr Matthew Watto, here with my great friend Dr Paul Nelson Williams. Today we're going to be talking about foot and ankle pain. We had a great podcast episode on this, The Thrill of Victory and the Agony of the Feet, with Dr Joan Ritter. Paul, let's start with ankle sprains. Give me a pearl. P...

Is It Time to Write a Prescription for Meditation Instead of Medication in Type 2 Diabetes?
https://www.medscape.com/viewarticle/984551

Nov 30th, 2022 - A recently published meta-analysis suggested that the utilization of mind-body practices in people living with type 2 diabetes can help significantly improve glycemic control. Multiple media outlets extolled the findings that these techniques could lead to a mean A1c reduction of 0.84%, which is similar to or better than what is achieved with many pharmacotherapies developed for the management ...

AstraZeneca Boosts Cancer Portfolio With $320 Million Neogene Deal
https://www.medscape.com/viewarticle/984703

Nov 30th, 2022 - (Reuters) -AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday, seeking to build its pipeline of cell-based cancer treatments. Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals su...

With Type 1 Diabetes Delay Possible, Focus Now on Screening
https://www.medscape.com/viewarticle/984748

Nov 30th, 2022 - The recent approval of teplizumab-mzwv (Tzield, Provention Bio) for the delay of type 1 diabetes by the US Food and Drug Administration is expected to advance efforts to increase screening to cost-effectively identify those at risk for the condition who would be eligible to receive the new treatment. The anti-CD3 monoclonal antibody was approved November 17 as the first disease-modifying therap...

Rituximab Raises Remission Rate in GPA Vasculitis
https://www.medscape.com/viewarticle/984760

Nov 30th, 2022 - More patients with granulomatosis with polyangiitis (GPA) were in remission at 6 months if they had received rituximab (Rituxan) rather than cyclophosphamide (Cytoxan) as induction therapy, according to a target trial emulation performed by the French Vasculitis Study Group (FVSG). Remission, which was defined as a score of zero on the validated Birmingham Vasculitis Activity Score (BVAS) and u...

One Dose of Acoziborole Led to Cure of 'Sleeping Sickness' Across Disease Stages
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/101970

Nov 29th, 2022 - A single dose of oral acoziborole proved to be efficacious and safe for adults and adolescents with gambiense human African trypanosomiasis (HAT), also known as "sleeping sickness," suggesting its promise in interrupting transmission, a single-arm phase II/III trial showed. Over 18 months of follow-up, the treatment success rate was 95.2% in those with late-stage disease and 98.1% in the evalua...

Metastasis-Directed Therapy May Delay ADT in Advanced Prostate Cancer
https://www.medpagetoday.com/hematologyoncology/prostatecancer/101967

Nov 29th, 2022 - Metastasis-directed therapy (MDT) in selected patients with recurrent oligometastatic prostate cancer led to PSA responses in a majority of patients and delayed initiation of hormonal therapy by 18 months, a retrospective study showed. Overall, 77 of 124 patients had PSA declines of more than 50% with surgery or stereotactic body radiation therapy (SBRT). In particular, surgery led to PSA respo...

Ultra-Long Stroke Transfers; Isotopes Return; Back-to-Back CPR During Half Marathon
https://www.medpagetoday.com/cardiology/prevention/101958

Nov 29th, 2022 - Persistent asthma was linked to higher carotid plaque burden and inflammation in the MESA cohort. (Journal of the American Heart Association) Hospitals can still make endovascular therapy work for stroke patients transferred from over 300 miles away, suggested a retrospective study from New Zealand and Australia. (Stroke) Good news during the medical radioisotope shortage: the global supply of ...

FOCUS-Rare success for Alzheimer's research unlocks hope for future therapies
https://www.reuters.com/article/health-alzheimers-targets/focus-rare-success-for-alzheimers-research-unlocks-hope-for-future-therapies-idUSL1N32O2E3

Nov 29th, 2022 - CHICAGO, Nov 29 (Reuters) - The first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai Co Ltd and Biogen reported in September that their therapy lecanemab cou...

Stool Transplants May Boost Immunotherapy Success in Melanoma
https://www.medscape.com/viewarticle/984710

Nov 29th, 2022 - In advanced and metastatic melanoma patients, fecal microbiota transplant (FMT) from healthy donors in advance of anti–PD-1 immunotherapy led to a 75% clinical benefit rate, defined as complete response, partial response, or stable disease that lasted 6 months or longer. The results come from a small, single arm phase 1 study whose primary endpoint was safety. "We know that the gut microbiome h...

UK's C4X Discovery Signs $400 Million Licensing Deal With AstraZeneca
https://www.medscape.com/viewarticle/984617

Nov 29th, 2022 - LONDON (Reuters) - British drug discovery company C4X Discovery said AstraZeneca had signed a licence worth up $402 million to develop an oral therapy for the treatment of inflammatory and respiratory diseases using its NRF2 Activator programme. C4XD said on Monday it would receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million up...

Atezolizumab (Tecentriq) Bladder Cancer Indication Withdrawn in US
https://www.medscape.com/viewarticle/984722

Nov 29th, 2022 - Atezolizumab (Tecentriq) is no longer approved in the United States for use in certain patients with bladder or urinary tract cancer. The drug is an anti-PD-L1 inhibitor immunotherapy, and continues to be approved for use in lung and liver cancer and melanoma. The manufacturer, Genentech, announced that it was voluntarily withdrawing the US indication for atezolizumab that covered its use in  a...

Will a One-Dose Drug Mean the End of Sleeping Sickness?
https://www.medscape.com/viewarticle/984736

Nov 29th, 2022 - A single dose of oral acoziborole resulted in a greater than 95% cure or probable cure rate for human African trypanosomiasis (HAT), also known as sleeping sickness, according to results from a clinical trial testing a one-dose experimental drug. The drug has "the potential to revolutionize treatment" for the disease, which remains endemic in sub-Saharan Africa, said Antoine Tarral, MD, head of...

New Studies Change Beliefs About Cardiovascular Disease
https://www.medscape.com/viewarticle/984181

Nov 29th, 2022 - This transcript has been edited for clarity. Recently, there have been a series of published studies in the realm of cardiovascular disease that have changed certain beliefs we've held in the past. I'm going to review a few of these. The first is the TIME study. The TIME study looked at whether it matters if you give antihypertensive agents in the morning or the evening. This was a prospective,...